Pharmaceuticals

A Swiss firm begins human trials for a non-glucose dialysis solution, aiming to end a 30-year reliance on problematic treatments for kidney patients.

Arrotex secures rights to an innovative, FDA-approved nanotech eye drop, promising faster, simpler recovery for thousands of surgical patients.

The FDA is reviewing a new, more affordable alternative to the costly arthritis drug Orencia, potentially saving patients and the healthcare system billions.

ABLi Therapeutics reports its drug risvodetinib is the first to lower toxic alpha-synuclein levels in a Phase 2 trial, heralding a new era for patients.

Sai Life Sciences' plan to hire 700+ professionals underscores a global shift, positioning India as a critical hub for pharmaceutical R&D and manufacturing.

MAIA Pharmaceuticals will bring Teribone™, a proven therapy used in Japan, to the US, aiming to solve the critical patient adherence crisis in osteoporosis care.

INmune Bio will present key Phase III results for CORDStrom, a systemic cell therapy for the devastating rare skin disease RDEB. Will it be a breakthrough?

A renewed deal between Inmar Intelligence and Premier, Inc. highlights the vital, unseen role of reverse logistics in pharmacy finance, compliance, and safety.

Pharma giant AbbVie raises its dividend, backed by robust financials and a powerful drug pipeline that signals a thriving post-Humira growth era.

Klothea Bio's trial for a 'longevity protein' drug in Honduras pushes the boundaries of science, but raises questions about offshore research and equity.

Innoviva prepares for a key investor conference, spotlighting its shift to specialty drugs and navigating questions on its diversified growth strategy.

Reunion Neuroscience hits the investor conference circuit, seeking capital to advance its groundbreaking psychedelic-inspired therapies for depression and anxiety.

With two strategic hires from TriNetX and Canon Medical, Avandra signals an aggressive push to unlock siloed medical imaging data for research and AI.

With a major €12.5M EU funding package, Step Pharma is fast-tracking dencatistat, a novel therapy targeting a key vulnerability in ovarian and endometrial cancers.

New data shows an AI-driven approach is enrolling IBD patients 3.4x faster, promising to accelerate the delivery of novel therapies to those in need.

Amid regional conflict, InterCure reports NIS 265M revenue, enters German market, and makes strategic US moves, showcasing remarkable resilience and growth.

Israeli cannabis firm InterCure posts 11% revenue growth in 2025, showing resilience after conflict and making its first major push into the booming German market.

With major grants from top foundations, Lario Therapeutics expands its precision neuroscience platform, offering new hope for complex neurological disorders.

With its CEO and CFO set for key conferences, Aptar will address investors following a strong sales quarter but facing questions on profitability.

After a major pipeline pivot, Keros Therapeutics faces investors with a new lead drug, a fortified balance sheet, and a high-stakes strategy to prove.